DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$2,516,000
-15.0%
3,500,0000.0%0.07%
-22.3%
Q1 2020$2,960,000
-36.1%
3,500,0000.0%0.09%
-36.5%
Q4 2019$4,632,0003,500,0000.15%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2020
NameSharesValueWeighting ↓
HIGHBRIDGE CAPITAL MANAGEMENT LLC 27,943,000$20,241,0001.72%
Worth Venture Partners, LLC 1,569,000$1,134,0000.56%
Context Capital Management, LLC 1,985,000$1,424,0000.55%
ADVENT CAPITAL MANAGEMENT /DE/ 16,703,000$12,060,0000.28%
CSS LLC/IL 6,825,000$4,985,0000.28%
SILVERBACK ASSET MANAGEMENT LLC 1,500,000$1,095,0000.27%
Polar Asset Management Partners Inc. 20,000,000$14,452,0000.24%
Senvest Management, LLC 5,000,000$3,621,0000.23%
FARALLON CAPITAL MANAGEMENT LLC 25,500,000$18,998,0000.15%
LINDEN ADVISORS LP 12,755,000$9,258,0000.15%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders